Analyzing Reneo Pharmaceuticals (RPHM) and The Competition

Reneo Pharmaceuticals (NASDAQ:RPHMGet Rating) is one of 937 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Reneo Pharmaceuticals to similar businesses based on the strength of its institutional ownership, valuation, analyst recommendations, risk, profitability, earnings and dividends.

Earnings and Valuation

This table compares Reneo Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Reneo Pharmaceuticals N/A -$39.77 million -0.48
Reneo Pharmaceuticals Competitors $1.83 billion $238.18 million -1.65

Reneo Pharmaceuticals’ competitors have higher revenue and earnings than Reneo Pharmaceuticals. Reneo Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and target prices for Reneo Pharmaceuticals and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Reneo Pharmaceuticals 0 0 6 0 3.00
Reneo Pharmaceuticals Competitors 6116 20665 43013 857 2.55

Reneo Pharmaceuticals presently has a consensus target price of $30.83, indicating a potential upside of 1,234.78%. As a group, “Pharmaceutical preparations” companies have a potential upside of 110.54%. Given Reneo Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Reneo Pharmaceuticals is more favorable than its competitors.

Profitability

This table compares Reneo Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Reneo Pharmaceuticals N/A -37.67% -27.26%
Reneo Pharmaceuticals Competitors -4,343.45% -115.55% -11.42%

Institutional and Insider Ownership

83.7% of Reneo Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.5% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.4% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Reneo Pharmaceuticals beats its competitors on 7 of the 12 factors compared.

Reneo Pharmaceuticals Company Profile (Get Rating)

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.